Skip to content

Immix Biopharma, Inc. IMMX Free cash flow yield

Free cash flow yield at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
9.6%-0.9pp
Johnson & Johnson logo
Johnson & JohnsonJNJ
3%-2.1pp
AbbVie logo
AbbVieABBV
5.2%+1.0pp
Allogene Therapeutics logo
Allogene TherapeuticsALLO
-18.4%-7.6pp
Regenxbio logo
RegenxbioRGNX
-54.7%-272pp
Kyverna Therapeutics, Inc. logo
Kyverna Therapeutics, Inc.KYTX
-27.4%-10.5pp

Other financials

Income statement

See full
Operating income-$10.8M-131%
Net income-$10.1M-122%
EPS (diluted)-$0.18-20.0%

Balance sheet

See full
Cash & equivalents$79.3M+398%
Total debt$1.0M-2.0%
Total equity$84.4M+779%
Total assets$95.8M+382%

Cash flow

See full
Operating cash flow-$9.8M-483%
CapEx$32.5K-52.0%
Free cash flow-$9.9M-462%

Valuation

See full
Market cap$691.97M+1,008%
Enterprise value$613.75M+1,190%

Returns & leverage

See full
Return on equity-74.4%-18.6pp
Debt / equity-0.1×
Current ratio8.8×+7.0×

Where this comes from

Calculated from Immix Biopharma, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immix Biopharma, Inc.'s free cash flow yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Immix Biopharma, Inc.'s free cash flow yield?
Immix Biopharma, Inc. (IMMX) reported free cash flow yield of -6.8% in Q1 2026.
How has Immix Biopharma, Inc.'s free cash flow yield changed year-over-year?
Immix Biopharma, Inc.'s free cash flow yield increased by 76.4% year-over-year, from -28.8% to -6.8%.
What is the long-term trend for Immix Biopharma, Inc.'s free cash flow yield?
Over 2 years (2021 to 2025), Immix Biopharma, Inc.'s free cash flow yield has grown at a 66.5% compound annual growth rate (CAGR), from -3.2% to -8.9%.
What does free cash flow yield mean?
Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.